Conservative management of chronic aortic dissection with underlying aortic aneurysm

Cardiovascular care continues to evolve in response to increasingly complex clinical realities, where advances in intervention, electrophysiology and population health must be integrated with a more critical appraisal of long-held assumptions. Across disciplines, there is a growing recognition that improving ...

Sudden cardiac arrest (SCA) in young adults (typically defined as individuals younger than 40 years) has emerged as an important yet under-recognized public health concern. Recent estimates suggest an incidence of approximately 1–4 cases per 100,000 person-years, underscoring the clinical and epidemiological relevance ...

Cardiovascular medicine continues to advance at a remarkable pace, driven by innovation, interdisciplinary collaboration and an ever-deepening understanding of disease mechanisms. As patient populations age and chronic conditions become increasingly complex, the field stands at the intersection of precision therapy, ...

The Evolut Low Risk trial (Transcatheter Aortic Valve Replacement With the Medtronic Transcatheter Aortic Valve Replacement System In Patients at Low Risk for Surgical Aortic Valve Replacement; ClinicalTrials.gov identifier: NCT02701283) provides reassuring evidence that transcatheter aortic valve replacement (TAVR) ...

Cardiovascular disease (CVD) is one of the major causes of morbidity and mortality throughout the world.1,2 While traditional risk factors are managed intensively, many individuals continue to have considerable residual risk, and emerging factors such as inflammatory mediators are being ...

Coronary artery dissection is a common occurrence during lesion preparation and after drug-coated balloon (DCB) inflation.1 Recent DCB studies focusing on coronary dissections have shown a few key findings: Their angiographic incidence varies between 35 and 60%. Non-flow-limiting dissections left untreated had ...

Despite advancements in mortality rates from cardiovascular disease (CVD) over the last 50 years, it remains the leading cause of death for women and the third leading cause for women aged 18 to 44.1 A 2011 report from the American Heart Association (AHA) starkly ...

Transthyretin amyloid cardiomyopathy (ATTR-CM) is an inexorably progressive and ultimately fatal cardiomyopathy characterized by the deposition of misfolded transthyretin (TTR) in the form of amyloid fibrils within the myocardium.1 Transthyretin amyloid (ATTR) fibrils are insoluble protease-resistant beta-pleated sheets that are ...

Hypertrophic cardiomyopathy (HCM) is a genetic cardiac abnormality characterized by left ventricular hypertrophy and diastolic dysfunction, primarily attributed to mutations in genes that encode sarcomeric proteins.1,2 The disease manifests in two broad phenotypes: obstructive HCM (oHCM), defined by dynamic left ...

Cardiovascular disease (CVD) continues to be the primary cause of mortality and morbidity globally with middle-aged women presenting with additional and possibly, overlooked risk factors.1 Despite several awareness programmes, there remain several gaps in the political education and representation needs ...

Cardiovascular disease (CVD) is a significant cause of morbidity and mortality in patients with type 2 diabetes mellitus (T2DM). An estimated 60–80% of patients with T2DM die of cardiovascular events.1,2 A bidirectional relationship has been noted between heart failure (HF) ...

This corrects the article: “Ioannou A. Evolution of Disease-modifying Therapy for Transthyretin Cardiac Amyloidosis. Heart International. 2024;18(1):30-37”. Two typography errors were included incorrectly due to an editorial error. In Table 1, “eplontersen” was incorrectly written as “eplomtersen”. This has been corrected ...